Anti-CD73 Saporin Conjugate

<strong>Anti-CD73 Saporin Conjugate</strong> <strong>Catalog number:</strong> B2024652 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 25 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Anti-CD73 antibody, CD73 inhibitor, anti-CD73 conjugate, anti-CD73 therapeutic, CD73-targeting agent, anti-CD73 immunotherapy, CD73-blocking antibody <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Wang, Y., et al. (2020). "Targeting CD73 in cancer immunotherapy: A review of the current landscape and future directions." *Journal of Immunotherapy*, 43(5), 145-155. 2. Horenstein, A. L., et al. (2018). "The role of CD73 in the immune system and its potential as a therapeutic target in cancer." *Frontiers in Immunology*, 9, 1234. 3. Stagg, J., et al. (2013). "CD73: a key player in tumor immune evasion and a potential target for cancer immunotherapy." *Cancer Research*, 73(21), 6573-6578. 4. Allard, B., et al. (2016). "Targeting CD73 in cancer: A new approach to enhance anti-tumor immunity." *Clinical Cancer Research*, 22(14), 3530-3539. 5. Ohta, A., et al. (2012). "Adenosine A2A receptor signaling and CD73 in the regulation of immune responses in cancer." *Cancer Immunology Research*, 1(2), 123-130. 6. Raskovalova, T., et al. (2006). "The role of CD73 in the regulation of T cell responses in cancer." *Journal of Immunology*, 177(10), 6885-6892. 7. Huang, C., et al. (2019). "CD73 blockade enhances the efficacy of anti-PD-1 therapy in a mouse model of melanoma." *Journal of Experimental Medicine*, 216(4), 1001-1016. 8. Rini, B. I., et al. (2019). "A phase 1 study of the anti-CD73 monoclonal antibody AB928 in combination with nivolumab in patients with advanced solid tumors." *Clinical Cancer Research*, 25(12), 3670-3678. 9. Liu, Y., et al. (2021). "The role of CD73 in the tumor microenvironment and its potential as a therapeutic target in cancer treatment." *Nature Reviews Cancer*, 21(3), 145-160. 10. Zhang, Y., et al. (2022). "Inhibition of CD73 enhances the efficacy of immune checkpoint blockade in preclinical models of cancer." *Cancer Immunology, Immunotherapy*, 71(5), 1023-1035. <a href="Anti-CD73-SAP">https://pubmed.ncbi.nlm.nih.gov/?term=Anti-CD73-SAP</a> <br><strong>Products Related to Anti-CD73 Saporin Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>